---
title: "Astrazeneca's second ADC drug has been approved for breast cancer in China"
description: "Astrazeneca announced that its second ADC drug, datopotamab deruxtecan (Dato-DXd), has been approved in China for the treatment of specific types of advanced breast cancer patients. The drug is suitab"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/254176767.md"
published_at: "2025-08-22T12:38:10.000Z"
---

# Astrazeneca's second ADC drug has been approved for breast cancer in China

> Astrazeneca announced that its second ADC drug, datopotamab deruxtecan (Dato-DXd), has been approved in China for the treatment of specific types of advanced breast cancer patients. The drug is suitable for adult patients with unresectable or metastatic hormone receptor-positive, HER2-negative breast cancer who have previously received endocrine therapy and experienced at least one line of chemotherapy. Datopotamab deruxtecan is a TROP2-targeting antibody-drug conjugate developed in collaboration between Astrazeneca and Daiichi Sankyo

AstraZeneca announced that injectable derazantinib (Dazhuoyou) has officially been approved in China for the treatment of adult patients with unresectable or metastatic hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative breast cancer who have previously received endocrine therapy and at least one line of chemotherapy in the advanced disease stage. Derazantinib is a targeted TROP2 antibody-drug conjugate (ADC) and is the second ADC drug developed in collaboration between AstraZeneca and Daiichi Sankyo to be introduced in China. (The Paper)

### Related Stocks

- [AZN.US - AstraZeneca](https://longbridge.com/en/quote/AZN.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Trump Strikes Again: AstraZeneca's Surprise Drug Deal Could Shake Big Pharma's Global Pricing Power | AstraZeneca has reached a drug-pricing deal with President Trump to reduce Medicaid drug prices, potentially reshaping B | [Link](https://longbridge.com/en/news/260941568.md) |
| ANALYSIS-AstraZeneca's US listing may pull other firms from London in its wake | AstraZeneca's decision to upgrade its U.S. listing while retaining its London presence may influence other UK firms to c | [Link](https://longbridge.com/en/news/259563996.md) |
| Advance Auto Parts’ Heavy Debt Load Raises Liquidity, Refinancing and Turnaround Risks | Advance Auto Parts Inc (AAP) is facing significant financial risks due to its heavy debt load, which may limit liquidity | [Link](https://longbridge.com/en/news/275997122.md) |
| Ibn Al Haytham Hospital FY Income 301,281 Dinars | Ibn Al Haytham Hospital Company PSC (IBNH.AM):IBN AL HAYTHAM HOSPITAL FY NET INCOME AFTER TAX 301,281 DINARSIBN AL HAYTH | [Link](https://longbridge.com/en/news/275996849.md) |
| Did Analyst Upgrades and Metal Price Tailwinds Just Shift Coeur Mining's (CDE) Investment Narrative? | Recent analyst upgrades for Coeur Mining, alongside rising gold and silver prices, have shifted focus on the company's c | [Link](https://longbridge.com/en/news/275995095.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.